Abbott India Ltd
₹ 27,121
1.53%
28 Mar
- close price
- Market Cap ₹ 57,632 Cr.
- Current Price ₹ 27,121
- High / Low ₹ 29,639 / 20,594
- Stock P/E 50.3
- Book Value ₹ 1,463
- Dividend Yield 0.66 %
- ROCE 41.1 %
- ROE 31.6 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 29.6%
- Company has been maintaining a healthy dividend payout of 76.8%
Cons
- Stock is trading at 18.5 times its book value
- The company has delivered a poor sales growth of 10.2% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Multinational
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Dec 2011 | Dec 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1,490 | 1,653 | 2,276 | 2,289 | 2,614 | 2,903 | 3,298 | 3,679 | 4,093 | 4,310 | 4,913 | 5,349 | 5,753 | |
1,315 | 1,451 | 2,009 | 1,977 | 2,250 | 2,505 | 2,774 | 3,074 | 3,336 | 3,388 | 3,832 | 4,143 | 4,350 | |
Operating Profit | 176 | 202 | 267 | 312 | 365 | 398 | 525 | 605 | 757 | 922 | 1,082 | 1,206 | 1,404 |
OPM % | 12% | 12% | 12% | 14% | 14% | 14% | 16% | 16% | 18% | 21% | 22% | 23% | 24% |
19 | 33 | 49 | 48 | 50 | 57 | 117 | 113 | 114 | 81 | 83 | 154 | 217 | |
Interest | 0 | 0 | 0 | 0 | 3 | 2 | 4 | 2 | 9 | 18 | 19 | 16 | 14 |
Depreciation | 15 | 19 | 22 | 15 | 14 | 16 | 16 | 17 | 60 | 58 | 66 | 70 | 70 |
Profit before tax | 180 | 215 | 295 | 344 | 398 | 436 | 621 | 699 | 803 | 926 | 1,080 | 1,274 | 1,536 |
Tax % | 33% | 33% | 33% | 34% | 36% | 37% | 35% | 36% | 26% | 25% | 26% | 25% | |
120 | 145 | 198 | 229 | 255 | 277 | 401 | 450 | 593 | 691 | 799 | 949 | 1,146 | |
EPS in Rs | 56.66 | 68.10 | 93.39 | 107.75 | 120.12 | 130.19 | 188.82 | 211.93 | 279.04 | 325.04 | 375.87 | 446.80 | 539.12 |
Dividend Payout % | 30% | 25% | 25% | 29% | 29% | 31% | 29% | 31% | 90% | 85% | 73% | 73% |
Compounded Sales Growth | |
---|---|
10 Years: | 12% |
5 Years: | 10% |
3 Years: | 9% |
TTM: | 9% |
Compounded Profit Growth | |
---|---|
10 Years: | 21% |
5 Years: | 19% |
3 Years: | 17% |
TTM: | 23% |
Stock Price CAGR | |
---|---|
10 Years: | 31% |
5 Years: | 30% |
3 Years: | 22% |
1 Year: | 25% |
Return on Equity | |
---|---|
10 Years: | 27% |
5 Years: | 28% |
3 Years: | 30% |
Last Year: | 32% |
Balance Sheet
Figures in Rs. Crores
Dec 2011 | Dec 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
Reserves | 523 | 626 | 767 | 916 | 1,174 | 1,366 | 1,672 | 1,987 | 2,410 | 2,581 | 2,799 | 3,167 | 3,088 |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 175 | 153 | 152 | 113 | 92 | |
253 | 260 | 351 | 436 | 421 | 679 | 723 | 932 | 940 | 1,086 | 1,253 | 1,254 | 1,315 | |
Total Liabilities | 797 | 907 | 1,139 | 1,374 | 1,616 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 4,516 |
80 | 109 | 98 | 96 | 108 | 110 | 81 | 105 | 270 | 251 | 271 | 237 | 225 | |
CWIP | 0 | 1 | 1 | 4 | 3 | 6 | 2 | 1 | 2 | 1 | 1 | 4 | 12 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
717 | 798 | 1,040 | 1,274 | 1,505 | 1,950 | 2,333 | 2,835 | 3,275 | 3,589 | 3,952 | 4,315 | 4,278 | |
Total Assets | 797 | 907 | 1,139 | 1,374 | 1,616 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 4,516 |
Cash Flows
Figures in Rs. Crores
Dec 2011 | Dec 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
24 | 101 | 155 | 215 | 249 | 307 | 153 | 499 | 626 | 727 | 948 | 893 | |
56 | -59 | -144 | -187 | -77 | -155 | -215 | -257 | -401 | -72 | -396 | -148 | |
-42 | -42 | -42 | -58 | -80 | -90 | -102 | -143 | -217 | -582 | -637 | -639 | |
Net Cash Flow | 38 | 1 | -31 | -30 | 91 | 62 | -165 | 99 | 8 | 73 | -86 | 107 |
Ratios
Figures in Rs. Crores
Dec 2011 | Dec 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 32 | 31 | 18 | 21 | 20 | 22 | 29 | 27 | 28 | 21 | 21 | 22 |
Inventory Days | 108 | 99 | 101 | 107 | 91 | 107 | 112 | 106 | 83 | 110 | 94 | 80 |
Days Payable | 51 | 38 | 38 | 54 | 56 | 101 | 92 | 116 | 104 | 116 | 122 | 109 |
Cash Conversion Cycle | 89 | 92 | 80 | 74 | 54 | 28 | 49 | 17 | 8 | 14 | -6 | -8 |
Working Capital Days | 46 | 49 | 36 | 30 | 32 | 21 | 63 | 22 | 14 | 7 | -4 | -5 |
ROCE % | 42% | 34% | 39% | 40% | 38% | 34% | 41% | 37% | 35% | 35% | 38% | 41% |
Documents
Announcements
- Intimation Under Regulation 30 1d
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2d - Copies of the advertisement published in Business Standard (All Editions in English) and Loksatta (in Marathi) today i.e., Wednesday, March 27, 2024, confirming the dispatch …
- Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 2d
- Closure of Trading Window 22 Mar
- Intimation Under Regulation 30 19 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Sep 2022TranscriptPPTREC
-
Jun 2021TranscriptPPT
Abbott Group
The company is a part of Abbott Laboratories. The group has a presence in 160+ countries across the globe with a legacy of 130+ years.[1] [2]